From the Guidelines
The dose schedule for the 4th cycle of Tecentriq (Atezolizumab) 1200mg/20mL and Avastin (Bevacizumab) is Atezolizumab: 1200 mg IV every 3 weeks and Bevacizumab: 15 mg/kg IV every 3 weeks.
Dose Calculation
- For Atezolizumab, the dose remains constant at 1200 mg IV every 3 weeks.
- For Bevacizumab, the dose is calculated based on the patient's weight, which is 15 mg/kg IV every 3 weeks.
Administration Considerations
- The treatment should be administered intravenously every 3 weeks, as indicated in the study 1.
- It is essential to consider the limitations of the evidence, including the lack of data on efficacy and adverse events in individuals with Child Turcotte Pugh B or C, as well as the potential for gastrointestinal bleeding with Bevacizumab.
- Patients should undergo endoscopic evaluation and treatment for esophageal varices before treatment, as recommended in the study 1.
Key Points
- The dose schedule for Atezolizumab and Bevacizumab remains the same for each cycle, including the 4th cycle.
- The treatment should be administered every 3 weeks, with careful consideration of the patient's weight for Bevacizumab dosing.
- Patients should be closely monitored for potential adverse effects, including gastrointestinal bleeding.
From the FDA Drug Label
DOSAGE AND ADMINISTRATION ... In the metastatic setting, administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. (2.2) ... Hepatocellular Carcinoma Administer TECENTRIQ as 840 mg every 2 weeks, 1200 mg every 3 weeks, or 1680 mg every 4 weeks. Administer TECENTRIQ prior to bevacizumab when given on the same day. Bevacizumab is administered at 15 mg/kg every 3 weeks. (2. 2)
The dose schedule for the 4th cycle of Tecentriq (Atezolizumab) 1200mg/20mL and Avastin (Bevacizumab) is:
- Tecentriq (Atezolizumab): 1200 mg every 3 weeks
- Avastin (Bevacizumab): 15 mg/kg every 3 weeks 2
From the Research
Dose Schedule for Tecentriq (Atezolizumab) and Avastin (Bevacizumab)
The dose schedule for the 4th cycle of Tecentriq (Atezolizumab) 1200mg/20mL and Avastin (Bevacizumab) 1200mg/48mL is as follows:
- Atezolizumab: 1200 mg intravenously every 3 weeks 3, 4, 5, 6
- Bevacizumab: 15 mg/kg intravenously every 3 weeks 3, 4, 5, 6
Administration
Both drugs are administered intravenously every 3 weeks. The specific dose and administration schedule may vary depending on the patient's condition and the treating physician's discretion.
Key Points
- The dose schedule is based on studies that evaluated the efficacy and safety of atezolizumab and bevacizumab in various types of cancer, including hepatocellular carcinoma and non-small cell lung cancer 3, 4, 5, 6
- The studies demonstrated that the combination of atezolizumab and bevacizumab was associated with improved clinical outcomes, including progression-free survival and overall survival 3, 5, 6
- The most common adverse events associated with the combination therapy were hypertension, proteinuria, and fatigue 3, 4, 5, 6